Gene Therapy for HIV-1 Infection

  • Donald B. Kohn
  • Nava Sarver
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)


The potential of gene-based therapy as a treatment of HIV/AIDS has been receiving considerable attention in recent years (for review see 1,2,3). Gene therapy is based on the notion that transfer of a therapeutic gene into target cells will render them resistant to HIV-1 replication. Infusion of cells protected by in vitro gene therapy into the patient may thus limit virus spread and delay disease progression.


Gene Therapy Umbilical Cord Blood Human Immunodeficiency Virus Replication Hammerhead Ribozyme Gene Delivery Vector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sarver N and Rossi JJ. Gene therapy for HIV-1 infection: progress and prospects. J NIH Res, 1993; 5: 63–67.Google Scholar
  2. 2.
    Yu M, Poeschla E, Wong-Staal F. Progress towards gene therapy for HIV infection. Gene Therapy, 1994; 1: 13–26.PubMedGoogle Scholar
  3. 3.
    Bridges SH and Sarver N. Gene therapy and immune restoration for HIV disease. Lancet, 1995 (in press).Google Scholar
  4. 4.
    Kohn DB. The current status of gene therapy using hematopoietic stem cells. Current Opinions in Pediatrics 7 (1): 1995 (in Press).Google Scholar
  5. 5.
    Miller AD. Retroviral vectors. Curr Top Microbiol Immunol, 1992; 158: 1–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Current Topics in Microbiology and Immunology, 1992; 158: 97–129.PubMedCrossRefGoogle Scholar
  7. 7.
    Podsakoff G, Wong KK Jr, Chatterjee S. Efficient gene transfer into nondividing cells by adenoassociated virus-based vectors. J Virol, 1994; 68: 5656–5666.PubMedGoogle Scholar
  8. 8.
    Woffendin C, Yang ZY, Udaykumar, et al. Nonviral and viral delivery of a human immunodeficiency protective gene into primary human T cells. Proc Natl Acad Sci (USA), 1994; 91: 11581–11585.CrossRefGoogle Scholar
  9. 9.
    Sarver N, Canton EM, Chang PS, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science, 1990; 247: 1222–1225.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhou C, Bahner I, Larson G, et al. Anti-HIV-1 hammerhead ribozymes transduced by retroviral vectors inhibit HIV-1 replication in human T lymphocytes. Gene (in press).Google Scholar
  11. 11.
    Cullen BR. Human immunodeficiency virus as a prototypic complex retrovirus. J Virol, 1991; 65: 1053 1056.Google Scholar
  12. 12.
    Bahner I, Zhou C, Yu X-J, et al. Comparison of trans-dominant Inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol. 1993; 67: 3199–3207.PubMedGoogle Scholar
  13. 13.
    Malim MH, Freimuth WW, Liu J, et al. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med, 1992; 176: 1197–1201.Google Scholar
  14. 14.
    Bevec D, Dobrovnik M, Hauber J, Bohnlein E. Inhibition of human immunodeficiency virus type I replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci (USA), 1992; 89: 9870–9874.CrossRefGoogle Scholar
  15. 15.
    Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Over expression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell, 1990; 63: 601–608.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee TC, Sullenger BA, Gallardo HF, et al. Over expression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol, 1992; 4: 66–74.PubMedGoogle Scholar
  17. 17.
    Lee SW. Gallardo HF, Gilboa E, Smith C. Inhibition of human immunodeficiency virus type 1 in human T-cells by a potent RRE decoy comprised of the 13-nucleotide minimal Rev-binding domain. J Virol, 1994; 68: 8254–8264.PubMedGoogle Scholar
  18. 18.
    Karlsson S. Treatment of Genetic Defects in Hematopoietic Cell Functions by Gene Transfer. Blood, 1991; 78: 2481–2492.PubMedGoogle Scholar
  19. 19.
    Bodine DM, Moritz T, Donahue RE, et al. Long-term in vivo expression of a mucine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells. Blood, 1993; 82: 1975–1980.PubMedGoogle Scholar
  20. 20.
    Van Beusechem VW, Kakler A, Meidt PI, Valerio D. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone marrow cells. Proc Natl Acad Sci (USA), 1992; 79: 7640–7644.CrossRefGoogle Scholar
  21. 21.
    Kiem HP, Darovsky B, von Kalle C, et al. Retrovirus-mediated gene transduction into canine peripheral blood repopulating cells. Blood, 1994; 83: 1467–1473.PubMedGoogle Scholar
  22. 22.
    Krall WJ, Challita PM, Perlmutter LS, et al. Cells expressing human glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous system microglia after mucine bone marrow transplantation. Blood, 1994; 83: 2373–2348.Google Scholar
  23. 23.
    Kasahara N, Dozy A, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science, 1994; 266: 1373–1376.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Donald B. Kohn
  • Nava Sarver

There are no affiliations available

Personalised recommendations